Peter Feldman, PhD

Safety Profile of Adjunctive Pimavanserin in the ENHANCE Study, a Phase 3 Trial for the Potential Treatment of Schizophrenia in Patients With an Inadequate Response to Antipsychotic Treatment

Many patients with schizophrenia do not respond fully to antipsychotic treatment despite adherence. Evidence supporting polypharmacy is limited and adding another antipsychotic is associa...

Dragana Bugarski-Kirola , MD, MBA, MSc;

Srdjan Stankovic , MD, MSPH;

I-Yuan Liu , MSc;

Rene Nunez , MD;

Ramzey Odetalla , PA, MSc;

Mohammed Bari , MD;

Istvan Bitter , MD, PhD, DSc;

Peter Feldman , PhD;

10/08/2020

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

See Full Calendar

Peter Feldman, PhD

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products